GlassScriptPhysician profile
Ronak P Patel
NPI 1255872602
$4,487.76
in general payments reported to CMS, 2019-2025
44 companies · $1,012 in 2025
The $1,012 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $150 · 2021: $224 · 2022: $630 · 2023: $1,156 · 2024: $1,316 · 2025: $1,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,667 · Consulting Fee: $818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,666.84 |
| Consulting Fee | $817.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $817.50 | 2024 | Rybrevant |
| Merck Sharp & Dohme LLC | $499.71 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $364.66 | 2020-2025 | Reblozyl, Pomalyst |
| Incyte Corporation | $285.06 | 2020-2025 | Jakafi, Niktimvo, Monjuvi |
| Genzyme Corporation | $231.02 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $216.09 | 2023-2025 | |
| Amgen INC. | $182.38 | 2021-2023 | Kyprolis |
| Astrazeneca Pharmaceuticals LP | $163.09 | 2023-2025 | Enhertu, Lynparza, Tagrisso |
| Abbvie INC. | $145.74 | 2022-2025 | |
| Astellas Pharma US INC | $104.28 | 2022-2025 | Padcev, Xtandi |
| Servier Pharmaceuticals LLC | $87.68 | 2023-2025 | |
| Lilly USA, LLC | $86.25 | 2022-2025 | Jaypirca, Verzenio, Zepbound |
| Deciphera Pharmaceuticals INC. | $77.16 | 2023-2025 | Qinlock, Romvimza |
| Takeda Pharmaceuticals U.S.A., INC. | $75.44 | 2022-2023 | Iclusig |
| Sobi, INC | $74.76 | 2022-2025 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $73.11 | 2023-2025 | Enhertu |
| Janssen Biotech, INC. | $68.58 | 2023-2025 | Akeega, Erleada, Carvykti |
| Ipsen Biopharmaceuticals, INC | $64.78 | 2022-2023 | Somatuline Depot, Onivyde |
| E.R. Squibb & Sons, L.L.C. | $64.65 | 2023-2024 | Opdivo |
| Exelixis INC. | $63.53 | 2023-2025 | Cabometyx |
| Pfizer INC. | $63.32 | 2023-2024 | |
| Gilead Sciences, INC. | $60.96 | 2023-2025 | Trodelvy |
| Octapharma USA, INC. | $60.17 | 2023-2024 | Octagam Immune Globulin (Human), Panzyga |
| Recordati_rare_diseases_inc. | $53.75 | 2023-2025 | Enjaymo, Sylvant, Panhematin |
| Seagen INC. | $43.67 | 2023 | Tukysa, Padcev |
| Array Biopharma INC | $42.38 | 2024-2025 | Lorbrena, Xalkori, Mektovi |
| Bayer Healthcare Pharmaceuticals INC. | $42.02 | 2023 | |
| Glaxosmithkline, LLC. | $33.76 | 2025 | Zejula, Jemperli |
| Legend Biotech USA INC. | $25.85 | 2025 | Carvykti |
| Jazz Pharmaceuticals INC. | $24.87 | 2021 | |
| Epizyme, INC. | $24.53 | 2020 | |
| Taiho Oncology, INC. | $23.58 | 2023 | |
| Kite Pharma, INC. | $22.34 | 2023 | Yescarta |
| Genmab U.S., INC. | $21.84 | 2023 | Epkinly |
| Genentech USA, INC. | $21.71 | 2022 | |
| Emd Serono, INC. | $21.22 | 2023 | Tepmetko |
| Beigene USA, INC. | $21.05 | 2024 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $21.05 | 2023 | Epkinly, Imbruvica |
| Eisai INC. | $19.87 | 2025 | |
| Rigel Pharmaceuticals, INC. | $19.76 | 2025 | Gavreto, Rezlidhia, Tavalisse |
| Alnylam Pharmaceuticals INC. | $19.43 | 2025 | Givlaari |
| Cti Biopharma Corp. | $18.69 | 2023 | Vonjo |
| Aadi Bioscience, INC. | $18.39 | 2025 | Fyarro |
| Adc Therapeutics America, INC. | $18.08 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronak Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.